EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A microfluidic approach reveals ongoing disease activity in thrombotic thrombocytopenic purpura patients despite clinical remission

Adela Constantinescu-Bercu, Sabina McCann, Bertina Dragunaite, Raphael Sivera, Yishi Tan, Louisa Keogh, Karen Vanhoorelbeke, Heidi Rossmann, Bernhard Lämmle, Rens de Groot, Marie Scully

Journal of Thrombosis and Haemostasis · 2025

DOI: 10.1016/j.jtha.2025.06.027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025. Verfasst von Adela Constantinescu-Bercu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Haemostasis Research Unit, Institute for Cardiovascular Science, University College London, London, UK. Electronic address: a.constantinescu-bercu@uc…. Hauptthemen laut MEDLINE: Purpura, Thrombotic Thrombocytopenic, Blood Platelets, Microfluidic Analytical Techniques, Lab-On-A-Chip Devices. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: LifeArc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Thrombotic thrombocytopenic purpura (TTP) patients with reduced ADAMTS-13 activity could benefit from a dynamic assay that comprehensively reflects disease activity and shows adequacy of treatment. OBJECTIVES: To use a microfluidic assay to monitor thrombogenicity in TTP patients. METHODS: Fluorescently-labeled whole blood was perfused through channels coated with collagen or an antibody against von Willebrand factor (VWF) A3 domain and monitored in real-time. RESULTS: Platelet coverage was significantly increased on both surfaces in samples from congenital TTP (cTTP) and, importantly, immune TTP (iTTP) patients with normal platelet counts but ADAMTS-13 activity below normal range (median activity, 34.5 IU/dL). There was heterogeneity in thrombogenicity in iTTP, despite patients being in clinical remission. Surface coverage on anti-VWF A3 positively correlated with VWF antigen and activity, and with VWF:ADAMTS-13 ratio. On collagen, samples from cTTP and iTTP patients with subnormal ADAMTS-13 activity formed extensive thrombi with increased area and length, positively correlating with VWF:ADAMTS-13. In iTTP, these parameters were normalized in complete remission (ADAMTS-13 activity within normal range). In cTTP, there was a significant reduction in platelet coverage, thrombi area, and length when patients were receiving treatment, particularly with recombinant ADAMTS-13 prophylaxis compared with standard o -care. CONCLUSION: We successfully used a flow-based assay to investigate VWF-dependent platelet recruitment as a rapid and sensitive monitoring tool for TTP patients, which is an important research tool to study thrombogenesis. Our results using this assay, as a marker of ongoing microvascular thrombi formation, confirm the need to normalize ADAMTS-13 activity levels in iTTP patients in clinical remission and the benefit of using recombinant ADAMTS-13 in cTTP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purpura, Thrombotic ThrombocytopenicBlood PlateletsMicrofluidic Analytical TechniquesLab-On-A-Chip DevicesHumansADAMTS13 Proteinvon Willebrand FactorRemission InductionMaleFemaleMiddle AgedAdultPredictive Value of TestsPlatelet Function Tests

Stichwörter der Autor:innen

ADAMTS-13microfluidicsthrombogenicitythrombotic thrombocytopenic purpura

Substanzen

ADAMTS13 Proteinvon Willebrand FactorADAMTS13 protein, human

Autor:innen und Institutionen

  • Haemostasis Research Unit, Institute for Cardiovascular Science, University College London, London, UK. Electronic address: a.constantinescu-bercu@ucl.ac.uk.
  • Special Coagulation, Health Services Laboratories, London, UK.
  • Haemostasis Research Unit, Institute for Cardiovascular Science, University College London, London, UK.
  • Department of Haematology, University College London Hospital, London, UK.
  • Laboratory for Thrombosis Research, KU Leuven Campus Kulak, Kortrijk, Belgium.
  • Center for Thrombosis and Haemostasis, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.

Förderung

  • LifeArc

Zitieren

APA

Constantinescu-Bercu, A., McCann, S., Dragunaite, B., Sivera, R., Tan, Y., Keogh, L., Vanhoorelbeke, K., Rossmann, H., Lämmle, B., de Groot, R., & Scully, M. (2025). A microfluidic approach reveals ongoing disease activity in thrombotic thrombocytopenic purpura patients despite clinical remission. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2025.06.027

Vancouver

Constantinescu-Bercu A, McCann S, Dragunaite B, Sivera R, Tan Y, Keogh L, et al. A microfluidic approach reveals ongoing disease activity in thrombotic thrombocytopenic purpura patients despite clinical remission. Journal of Thrombosis and Haemostasis. 2025. doi:10.1016/j.jtha.2025.06.027

BibTeX
@article{ConstantinescuBercu2025,
  author = {Constantinescu-Bercu, Adela and McCann, Sabina and Dragunaite, Bertina and Sivera, Raphael and Tan, Yishi and Keogh, Louisa and Vanhoorelbeke, Karen and Rossmann, Heidi and Lämmle, Bernhard and de Groot, Rens and Scully, Marie},
  title = {A microfluidic approach reveals ongoing disease activity in thrombotic thrombocytopenic purpura patients despite clinical remission},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2025},
  doi = {10.1016/j.jtha.2025.06.027}
}
Kostenlos starten →